All In Biotech

Drug Trial Radar · NCT07350577

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Pharmacosymics of Single Ascending Doses of Intravenously Administerted ALTB-268 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Nov 17, 2025

Primary completion

Apr 6, 2026

Study completion Apr 6, 2026

Sponsor

Lead sponsor
AltruBio Inc.Industry
Sponsor type
Industry
First posted
Jan 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of intravenously administrated ALTB-268 in healthy participants.

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • ALTB-268Biological

    monoclonal antibody

  • PlaceboOther

    Saline solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of ALTB-268 following intravenous (IV) infusion in healthy participants - Adverse EventsTime frame: Through study completion, up to day 71 of the study
  2. To evaluate the safety and tolerability of ALTB-268 following intravenous (IV) infusion in healthy participants - Infusion Site AssessmentsTime frame: Through study completion, up to day 71 of the study
  3. To evaluate the safety and tolerability of ALTB-268 following intravenous (IV) infusion in healthy participants - C-SSRSTime frame: Through study completion, up to day 71 of the study
  4. To evaluate the safety and tolerability of ALTB-268 following intravenous (IV) infusion in healthy participants - PHQ-8Time frame: Through study completion, up to day 71 of the study
  5. To evaluate the safety and tolerability of ALTB-268 following intravenous (IV) infusion in healthy participants - Clinical Laboratory TestTime frame: Through study completion, up to day 71 of the study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Syneos Health Clinical Research Services, LLC

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.